Tags

Type your tag names separated by a space and hit enter

The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
Pharmacol Res. 2016 09; 111:251-263.PR

Abstract

There is considerable evidence to support the role of anandamide (AEA), an endogenous ligand of cannabinoid receptors, in neuropathic pain modulation. AEA also produces effects mediated by other biological targets, of which the transient receptor potential vanilloid type 1 (TRPV1) has been the most investigated. Both, inhibition of AEA breakdown by fatty acid amide hydrolase (FAAH) and blockage of TRPV1 have been shown to produce anti-nociceptive effects. Recent research suggests the usefulness of dual-action compounds, which may afford greater anti-allodynic efficacy. Therefore, in the present study, we examined the effect of N-arachidonoyl-serotonin (AA-5-HT), a blocker of FAAH and TRPV1, in a rat model of neuropathic pain after intrathecal administration. We found that treatment with AA-5-HT increased the pain threshold to mechanical and thermal stimuli, with highest effect at the dose of 500nM, which was most strongly attenuated by AM-630, CB2 antagonist, administration. The single action blockers PF-3845 (1000nM, for FAAH) and I-RTX (1nM, for TRPV1) showed lower efficacy than AA-5-HT. Moreover AA-5-HT (500nM) elevated AEA and palmitoylethanolamide (PEA) levels. Among the possible targets of these mediators, only the mRNA levels of CB2, GPR18 and GPR55, which are believed to be novel cannabinoid receptors, were upregulated in the spinal cord and/or DRG of CCI rats. It was previously reported that AA-5-HT acts in CB1 and TRPV1-dependent manner after systemic administration, but here for the first time we show that AA-5-HT action at the spinal level involves CB2, with potential contributions from GRP18 and/or GPR55 receptors.

Authors+Show Affiliations

Laboratory of Pain Pathophysiology, Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland; Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland. Electronic address: n.malek@if-pan.krakow.pl.Laboratory of Pain Pathophysiology, Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland; Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland. Electronic address: mkos@if-pan.krakow.pl.Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland. Electronic address: makuch@if-pan.krakow.pl.Laboratory of Pain Pathophysiology, Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland; Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland. Electronic address: pajak@if-pan.krakow.pl.Laboratory of Pain Pathophysiology, Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland; Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland. Electronic address: meshugemk@gmail.com.Endocannabinoid Research Group, Institute of Biomolecular Chemistry⿿C.N.R., Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli (NA), Italy. Electronic address: fpiscitelli@icb.cnr.it.Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland. Electronic address: przebar@if-pan.krakow.pl.Endocannabinoid Research Group, Institute of Biomolecular Chemistry⿿C.N.R., Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli (NA), Italy. Electronic address: vincenzo.dimarzo@icb.cnr.it.Laboratory of Pain Pathophysiology, Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland; Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland. Electronic address: starow@if-pan.krakow.pl.

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27326920

Citation

Malek, Natalia, et al. "The Multiplicity of Spinal AA-5-HT Anti-nociceptive Action in a Rat Model of Neuropathic Pain." Pharmacological Research, vol. 111, 2016, pp. 251-263.
Malek N, Kostrzewa M, Makuch W, et al. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. Pharmacol Res. 2016;111:251-263.
Malek, N., Kostrzewa, M., Makuch, W., Pajak, A., Kucharczyk, M., Piscitelli, F., Przewlocka, B., Di Marzo, V., & Starowicz, K. (2016). The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. Pharmacological Research, 111, 251-263. https://doi.org/10.1016/j.phrs.2016.06.012
Malek N, et al. The Multiplicity of Spinal AA-5-HT Anti-nociceptive Action in a Rat Model of Neuropathic Pain. Pharmacol Res. 2016;111:251-263. PubMed PMID: 27326920.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. AU - Malek,Natalia, AU - Kostrzewa,Magdalena, AU - Makuch,Wioletta, AU - Pajak,Agnieszka, AU - Kucharczyk,Mateusz, AU - Piscitelli,Fabiana, AU - Przewlocka,Barbara, AU - Di Marzo,Vincenzo, AU - Starowicz,Katarzyna, Y1 - 2016/06/17/ PY - 2016/04/01/received PY - 2016/05/25/revised PY - 2016/06/11/accepted PY - 2016/6/22/entrez PY - 2016/6/22/pubmed PY - 2018/1/6/medline KW - Cannabinoid receptors KW - Endocannabinoids KW - FAAH KW - N-acylethanolamines KW - Neuropathic pain KW - TRPV1 SP - 251 EP - 263 JF - Pharmacological research JO - Pharmacol. Res. VL - 111 N2 - There is considerable evidence to support the role of anandamide (AEA), an endogenous ligand of cannabinoid receptors, in neuropathic pain modulation. AEA also produces effects mediated by other biological targets, of which the transient receptor potential vanilloid type 1 (TRPV1) has been the most investigated. Both, inhibition of AEA breakdown by fatty acid amide hydrolase (FAAH) and blockage of TRPV1 have been shown to produce anti-nociceptive effects. Recent research suggests the usefulness of dual-action compounds, which may afford greater anti-allodynic efficacy. Therefore, in the present study, we examined the effect of N-arachidonoyl-serotonin (AA-5-HT), a blocker of FAAH and TRPV1, in a rat model of neuropathic pain after intrathecal administration. We found that treatment with AA-5-HT increased the pain threshold to mechanical and thermal stimuli, with highest effect at the dose of 500nM, which was most strongly attenuated by AM-630, CB2 antagonist, administration. The single action blockers PF-3845 (1000nM, for FAAH) and I-RTX (1nM, for TRPV1) showed lower efficacy than AA-5-HT. Moreover AA-5-HT (500nM) elevated AEA and palmitoylethanolamide (PEA) levels. Among the possible targets of these mediators, only the mRNA levels of CB2, GPR18 and GPR55, which are believed to be novel cannabinoid receptors, were upregulated in the spinal cord and/or DRG of CCI rats. It was previously reported that AA-5-HT acts in CB1 and TRPV1-dependent manner after systemic administration, but here for the first time we show that AA-5-HT action at the spinal level involves CB2, with potential contributions from GRP18 and/or GPR55 receptors. SN - 1096-1186 UR - https://www.unboundmedicine.com/medline/citation/27326920/The_multiplicity_of_spinal_AA_5_HT_anti_nociceptive_action_in_a_rat_model_of_neuropathic_pain_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1043-6618(16)30566-7 DB - PRIME DP - Unbound Medicine ER -